Umbilical cord blood transplant for older adults with acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether using umbilical cord blood as a stem cell transplant can improve outcomes for older adults with intermediate- or high-risk acute myeloid leukemia (AML) who are in remission. It may help reduce the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 60 and 80 years old.
- You must have acute myeloid leukemia (AML) that is in remission after initial treatment, with specific genetic features.
- You cannot have a subtype called acute promyelocytic leukemia (APL).
- Your liver and kidney function must be adequate, and your heart must pump well enough.
- You must be able to follow the study plan and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
This trial tests a special combination of chemotherapy drugs (thiotepa, fludarabine, ara-C, busulfan) and a growth factor (G-CSF) to prepare your body for a transplant using donated umbilical cord blood. It is for older adults (60-69) with blood cancers who cannot use a matched family donor.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.